SL
SRPT icon

Salomon & Ludwin’s Sarepta Therapeutics SRPT Stock Holding History

Salomon & Ludwin’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8K Buy
921
+67
+8% +$1.27K ﹤0.01% 1278
2026
Q1 		$19.8K Buy
854
+30
+4% +$581 ﹤0.01% 1088
2025
Q4 		$17.4K Buy
824
+347
+73% +$7.31K ﹤0.01% 1015
2025
Q3 		$10.8K Buy
+477
New +$8.5K ﹤0.01% 1248

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Salomon & Ludwin's SRPT Position: Q2 2026 in Review

Salomon & Ludwin increased its Sarepta Therapeutics (SRPT) stake by 7.8% in Q2 2026, buying an estimated $1.27K and bringing the position to 921 shares worth $16.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1278.

Salomon & Ludwin first reported a position in SRPT in Q3 2025 and has held it in 4 quarters since. The position peaked at $19.8K in Q1 2026. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Salomon & Ludwin held 921 shares of Sarepta Therapeutics worth $16.8K as of Q2 2026.
  • Salomon & Ludwin bought 67 Sarepta Therapeutics shares in Q2 2026, an estimated $1.27K.
  • Sarepta Therapeutics made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #1278 holding.
  • Salomon & Ludwin first reported a position in Sarepta Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Salomon & Ludwin's Sarepta Therapeutics position peaked at $19.8K in Q1 2026.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.